Advancing Oncology Drug Development, Approval and Access Through Multi-Stakeholder Collaboration

2,644
Total downloads
20k
Total views and downloads

Articles

ORIGINAL RESEARCH

Published on 12 Dec 2025

Effect of the national reimbursement drug list negotiation policy on utilization of negotiated anticancer drugs in Chinese public hospital: a quasi-natural experiment

Gang Liu
Cui Li
Hezheng Sun
Huan Liu
Xin Zhang
Kexin Wang
Yanping Wang
Qunhong Wu
Linghan Shan

doi 10.3389/fpubh.2025.1662346

1,354 views

ORIGINAL RESEARCH

Published on 26 Sep 2025

Scientific and regulatory progress in advancing paediatric oncology drug development in the EU and in the US

Giorgio Reggiardo
Alessandra Natale
Nicola Santoro
Viviana Giannuzzi
Claudia Pansieri
Mariagrazia Felisi
Donato Bonifazi
Adriana Ceci

doi 10.3389/fmed.2025.1642279

1,844 views

DATA REPORT

Published on 25 Sep 2025

An analysis of FDA drug approvals for oncological hematological malignancies in relation to companion diagnostics

Jan Trøst Jørgensen

doi 10.3389/fonc.2025.1635491

3,676 views

SYSTEMATIC REVIEW

Published on 21 Aug 2025

Progress, impacts and lessons from market shaping in the past decade: a systematic review

Wenhui Mao
Katharine Olson
Elina Urli Hodges
Krishna Udayakumar

doi 10.3389/fpubh.2025.1614471

2,075 views
1 citation

PERSPECTIVE

Published on 02 Jul 2025

Value attribution for oncology combination regimens: going beyond frameworks to balance innovation, access, and affordability

Jennifer G. Gaultney
Daniel Ollendorf
Medha Sasane
Céline Fernandez
Krupa Paranjpe
Ting-Yen Chen
Hera Sandhu
Steven Simoens

doi 10.3389/fphar.2025.1590944

2,329 views

ORIGINAL RESEARCH

Published on 09 Jun 2025

Adoptive cellular immunotherapy combined with chemotherapy versus chemotherapy alone in Chinese patients with metastatic colorectal cancer: a cost-effectiveness analysis to inform drug pricing

Liman Huo
Ping Liang
Yangyang Duan
Yanmei Xu
Jianhua Tang
Qi Lv
Rui Feng

doi 10.3389/fonc.2025.1590319

1,882 views
1 citation

OPINION

Published on 18 Dec 2024

Personalized medicine: when the common becomes the rare

Daniel J. O'Connor

doi 10.3389/fmed.2024.1523594

2,909 views
1 citation

Share on

Frontiers in Medicine

Regulatory Science

Other participating journals

Frontiers in Public Health
- Public Health Policy
- 3.4 impact factor
- 5.5 citescore

Impact

20kTopic views
15kArticle views
2,644Article downloads

View impact

Articles

Effect of the national reimbursement drug list negotiation policy on utilization of negotiated anticancer drugs in Chinese public hospital: a quasi-natural experiment

Scientific and regulatory progress in advancing paediatric oncology drug development in the EU and in the US

An analysis of FDA drug approvals for oncological hematological malignancies in relation to companion diagnostics

Progress, impacts and lessons from market shaping in the past decade: a systematic review

Value attribution for oncology combination regimens: going beyond frameworks to balance innovation, access, and affordability

Adoptive cellular immunotherapy combined with chemotherapy versus chemotherapy alone in Chinese patients with metastatic colorectal cancer: a cost-effectiveness analysis to inform drug pricing

Personalized medicine: when the common becomes the rare

Frontiers in Medicine

Regulatory Science

Other participating journals

Frontiers in Public Health

Public Health Policy